Cephea Early Feasibility Study

NCT ID: NCT05061004

Last Updated: 2025-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-28

Study Completion Date

2031-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System

Group Type EXPERIMENTAL

Cephea Mitral Valve System

Intervention Type DEVICE

Transcatheter mitral valve replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cephea Mitral Valve System

Transcatheter mitral valve replacement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria.
* LVEF ≥ 30%
* In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery.

Exclusion Criteria

* Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function.
* Need for emergent or urgent surgery.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barathi Sethuraman

Role: STUDY_DIRECTOR

Abbott Structural Heart

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status RECRUITING

University of California - Davis Medical Center

Sacramento, California, United States

Site Status RECRUITING

Los Robles Regional Medical Center

Thousand Oaks, California, United States

Site Status ACTIVE_NOT_RECRUITING

Emory University Hospital

Atlanta, Georgia, United States

Site Status ACTIVE_NOT_RECRUITING

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status RECRUITING

Northwestern Memorial Hospital

Chicago, Illinois, United States

Site Status ACTIVE_NOT_RECRUITING

Via Christi Regional Medical Center - St. Francis Campus

Wichita, Kansas, United States

Site Status RECRUITING

University of Michigan

Ann Arbor, Michigan, United States

Site Status RECRUITING

Minneapolis Heart Institute

Minneapolis, Minnesota, United States

Site Status RECRUITING

New York-Presbyterian/Columbia University Medical Center

New York, New York, United States

Site Status NOT_YET_RECRUITING

Montefiore Medical Center - Moses Division

The Bronx, New York, United States

Site Status RECRUITING

Atrium Health - Carolinas Medical Center

Charlotte, North Carolina, United States

Site Status RECRUITING

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status RECRUITING

Allegheny General Hospital - ASRI

Pittsburgh, Pennsylvania, United States

Site Status ACTIVE_NOT_RECRUITING

Ascension Saint Thomas

Nashville, Tennessee, United States

Site Status RECRUITING

Vanderbilt Heart & Vascular Institute

Nashville, Tennessee, United States

Site Status NOT_YET_RECRUITING

Houston Methodist

Houston, Texas, United States

Site Status RECRUITING

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status ACTIVE_NOT_RECRUITING

Swedish Medical Center

Seattle, Washington, United States

Site Status NOT_YET_RECRUITING

Institut de Cardiologie de Montreal

Montreal, Quebec, Canada

Site Status COMPLETED

Institut de Cardiologie de Quebec

Québec, Quebec, Canada

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jennifer Studt

Role: CONTACT

+1 314-616-2790

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andjela Kremenovic

Role: primary

417-353-7177

Heather Houston

Role: primary

916-734-5155

Danielle Griffith

Role: primary

404-605-2958

Lindsey Steele

Role: primary

316-268-8092

Allison Schley

Role: primary

734-232-4319

Jennifer Nguyen

Role: primary

612-863-9291

Kate Dalton

Role: primary

212-342-1820

Tammy Rodriguez Guzman

Role: primary

(718) 920-6523

Montana Bright

Role: primary

Emily Tylicki

Role: primary

216-444-6950

Kolie Gasaway

Role: primary

(615) 222-3227

Deena Victor

Role: primary

Jennifer Nagel

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABT-CIP-10354

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The TRICURE EFS Study
NCT06506942 RECRUITING NA